UAE Liver Diseases Therapeutics Market Report 2022 to 2030

UAE Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the UAE Liver Disease Therapeutics market will reach a value of $194 Mn from $115 Mn in 2022, growing at a CAGR of 6.7% during 2022-2030. Liver Disease Therapeutics in UAE is dominated by domestic pharmaceutical companies such as Global pharma, Neopharma, and Julphar. The Liver Disease Therapeutics market in UAE is segmented into different types of disease and different therapy types. Some of the significant factors affecting the UAE Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10AEPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Vishwa Modhia

Buy Now

UAE Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the UAE Liver Disease Therapeutics market will reach a value of $194 Mn from $115 Mn in 2022, growing at a CAGR of 6.7% during 2022-2030.

United Arab Emirates (UAE) is a high-income, developing country located in the Middle East bordering the Gulf of Oman and the Persian Gulf. In comparison to other nations in the region, the prevalence of hepatitis B and C in the UAE is quite low, with an estimated 1.5 % of the population having chronic hepatitis B and 0.5 % having chronic hepatitis C. Cirrhosis is a common result of chronic liver disease, and it is estimated that roughly 7,000 persons in the UAE have cirrhosis. Cirrhosis can result in liver failure, malignancy, and death.

According to the latest WHO data published in 2020 Liver Disease Deaths in Arab Emirates reached 417 or 2.14% of total deaths. The age-adjusted Death Rate is 10.88 per 100,000 population ranking Arab Emirates #121 in the world. UAE's government spent 5.5 % of its GDP on healthcare in 2020.

UAE Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Aside from insurance coverage, the UAE government has launched a number of initiatives to improve access to liver therapies. The Dubai Health Authority, for example, has established the Dubai Hepatitis C Elimination Program to prevent, diagnose, and treat viral hepatitis. The initiative offers free hepatitis C testing and treatment at selected government hospitals and clinics. Non-alcoholic fatty liver disease (NAFLD) and the consequent non-alcoholic steatohepatitis (NASH) will be driving factors in the UAE's liver disease burden in the future years, owing to pandemic levels of obesity and type 2 diabetes mellitus (DM). The UAE is an outstanding regional trading hub for businesses. These aspects could boost the UAE Liver Disease Therapeutics market.

Market Restraints

The prevalence of Hepatitis B and C (HBV and HCV) in the UAE ranges from 0.24 to 1.64 per cent, but specialists point out that nearly 70 per cent of patients remain undiagnosed. Traditional remedies have a strong heritage in the UAE and can compete with Western-style therapies, including liver disease therapeutics. The UAE has made progress in improving access to liver therapeutics, there are still limitations and challenges that need to be addressed. Efforts to improve access to specialized medical facilities and healthcare professionals, reduce the cost of treatments, and address cultural and social barriers to seeking treatment could all help to improve outcomes for patients with liver diseases in the UAE. These factors may deter new entrants into the UAE Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Julphar: Julphar is a UAE-based pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Neopharma: Neopharma is an Abu Dhabi-based pharmaceutical company that develops and produces a wide range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Globalpharma: Globalpharma is a Dubai-based pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Medpharma: Medpharma is a Dubai-based pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin

Healthcare Policies and Reimbursement Scenarios

The Ministry of Health and Prevention (MOHAP) and the Dubai Health Authority (DHA). regulate and reimburse liver therapies in the UAE. The MOHAP oversees drug registration and approval in the UAE, including pharmaceuticals used to treat liver illnesses such as hepatitis B and C, liver cirrhosis, and other liver-related conditions. The UAE features a hybrid healthcare system that includes both public and private insurance choices. The Dubai Health Insurance Scheme (DHIS), the government's primary healthcare programme, provides health insurance coverage to all Dubai citizens, including those with pre-existing disorders such as liver disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.